Back to top
more

Esperion Therapeutics (ESPR)

(Real Time Quote from BATS)

$2.16 USD

2.16
661,315

+0.04 (1.89%)

Updated Nov 6, 2024 10:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Why Is United Therapeutics (UTHR) Up 2.1% Since Last Earnings Report?

by Zacks Equity Research

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Esperion Therapeutics (ESPR) Up 29.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Esperion (ESPR) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Esperion Therapeutics (ESPR) reports dismal second-quarter results, missing estimates for earnings and sales. However, shares rose on the back of ESPR's progress with its cardiovascular outcome study.

    Esperion Therapeutics (ESPR) Reports Q2 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -10.53% and 2.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Enanta Pharmaceuticals (ENTA) Stock Jumps 10.1%: Will It Continue to Soar?

    by Zacks Equity Research

    Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

    Esperion Therapeutics (ESPR) Down 15.1% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Esperion (ESPR) Up More Than 12% YTD: What's Driving the Rally?

    by Zacks Equity Research

    Esperion's (ESPR) marketed drugs are the key drivers of the stock. Sales of the drugs increase more than 100% during the first quarter. Strong sales growth is expected to continue in 2022 as well as 2023.

    Esperion (ESPR) Q1 Earnings Beat on Robust Demand for Drugs

    by Zacks Equity Research

    Esperion Therapeutics (ESPR) reports solid first-quarter results, beating estimates for earnings and sales. Cost-savings programs boost margins. Stock rallies.

    Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 3.12% and 21.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More

    by Zacks Equity Research

    Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.

    Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Should You Buy?

    by Zacks Equity Research

    Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Esperion's (ESPR) Drug Sales and Cost-Cutting Drive Stock YTD

    by Zacks Equity Research

    Esperion's (ESPR) stock rallies so far this year on higher product sales in the fourth quarter of 2021. Cost-saving initiatives to boost margins in 2022 are another key drivers.

    Why Is Esperion Therapeutics (ESPR) Up 29.1% Since Last Earnings Report?

    by Zacks Equity Research

    Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Esperion (ESPR) Q4 Earnings Beat, Product Sales Rise 49%

    by Zacks Equity Research

    Esperion Therapeutics (ESPR) reports solid fourth-quarter results, beating estimates for earnings and sales. Stock surges.

    Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 23.71% and 6.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    by Zacks Equity Research

    Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Why Is Esperion Therapeutics (ESPR) Down 24.5% Since Last Earnings Report?

    by Zacks Equity Research

    Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Implied Volatility Surging for Esperion Therapeutics (ESPR) Stock Options

    by Zacks Equity Research

    Investors need to pay close attention to Esperion Therapeutics (ESPR) stock based on the movements in the options market lately.

    Esperion (ESPR) Beats on Q3 Earnings, Lowers Expense Guidance

    by Zacks Equity Research

    Esperion Therapeutics (ESPR) reports solid third-quarter results, beating estimates for earnings and sales. However, the stock declines in pre-market trading.

    Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 8.39% and 17.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

    Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

    by Zacks Equity Research

    Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Esperion (ESPR) to Cut 40% Workforce, Revamp Cost Structure

    by Zacks Equity Research

    Esperion (ESPR) is set reduce its workforce by 40% and start targeted program savings to reduce its operational expense and deliver consistent growth.

    Esperion Therapeutics (ESPR) Down 5.9% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Esperion (ESPR) Q2 Loss Narrower Than Expected, Drug Price Up

    by Zacks Equity Research

    Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings but misses the same for sales. Stock down.

    Esperion Therapeutics (ESPR) Reports Q2 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 8.24% and -1.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?